ZA969812B - Novel quinoline derivatives. - Google Patents

Novel quinoline derivatives.

Info

Publication number
ZA969812B
ZA969812B ZA9609812A ZA969812A ZA969812B ZA 969812 B ZA969812 B ZA 969812B ZA 9609812 A ZA9609812 A ZA 9609812A ZA 969812 A ZA969812 A ZA 969812A ZA 969812 B ZA969812 B ZA 969812B
Authority
ZA
South Africa
Prior art keywords
quinoline derivatives
novel quinoline
novel
derivatives
quinoline
Prior art date
Application number
ZA9609812A
Other languages
English (en)
Inventor
Carlo Farina
Giuseppe Giardina
Mario Grugni
Luca Francesco Raveglia
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of ZA969812B publication Critical patent/ZA969812B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9609812A 1995-11-24 1996-11-22 Novel quinoline derivatives. ZA969812B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds

Publications (1)

Publication Number Publication Date
ZA969812B true ZA969812B (en) 1998-05-22

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609812A ZA969812B (en) 1995-11-24 1996-11-22 Novel quinoline derivatives.

Country Status (23)

Country Link
US (3) US6355654B1 (fr)
EP (1) EP0876348B1 (fr)
JP (1) JP4377454B2 (fr)
KR (1) KR19990071599A (fr)
CN (1) CN1207728A (fr)
AR (1) AR004970A1 (fr)
AT (1) ATE233243T1 (fr)
AU (1) AU722451B2 (fr)
BR (1) BR9611729A (fr)
CA (1) CA2238312A1 (fr)
CZ (1) CZ158198A3 (fr)
DE (1) DE69626416T2 (fr)
ES (1) ES2192621T3 (fr)
GB (1) GB9524137D0 (fr)
HU (1) HUP9903584A3 (fr)
IL (1) IL124352A0 (fr)
MX (1) MX9804106A (fr)
NO (1) NO310866B1 (fr)
NZ (1) NZ323389A (fr)
PL (1) PL326927A1 (fr)
TR (1) TR199800925T2 (fr)
WO (1) WO1997019928A1 (fr)
ZA (1) ZA969812B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
EP1891012A2 (fr) * 2005-06-03 2008-02-27 AstraZeneca AB Derives de quinoline utilises comme antagonistes de nk3
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504572A (ja) * 2005-08-02 2009-02-05 スミスクライン・ビーチャム・コーポレイション キノリン誘導体の合成方法
EP1915363A1 (fr) * 2005-08-11 2008-04-30 AstraZeneca AB Modulateurs récépteurs nk3 en tant qu'amides de quinoléine oxopyridyl
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
JP2009508944A (ja) * 2005-09-21 2009-03-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体リガンドとしてのｎ−オキソ複素環及びｎ−オキソ−アルキルキノリン−４−カルボキシアミド類
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
CN101410392A (zh) * 2006-01-27 2009-04-15 阿斯利康(瑞典)有限公司 酰胺取代的喹啉类化合物
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
MX344308B (es) * 2011-11-03 2016-12-13 Merck Sharp & Dohme Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2017072629A1 (fr) 2015-10-29 2017-05-04 Cadila Healthcare Limited Combinaison pharmaceutique d'antagoniste du récepteur nk3 et de biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246677T1 (de) * 1994-05-27 2003-08-15 Smithkline Beecham Farma Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
CA2238312A1 (fr) 1997-06-05
CN1207728A (zh) 1999-02-10
HUP9903584A3 (en) 2001-10-29
US20020077335A1 (en) 2002-06-20
NO310866B1 (no) 2001-09-10
US20020156097A1 (en) 2002-10-24
PL326927A1 (en) 1998-11-09
AU722451B2 (en) 2000-08-03
BR9611729A (pt) 1999-04-06
US6355654B1 (en) 2002-03-12
WO1997019928A1 (fr) 1997-06-05
KR19990071599A (ko) 1999-09-27
ATE233243T1 (de) 2003-03-15
DE69626416T2 (de) 2003-12-24
NO982332L (no) 1998-05-22
TR199800925T2 (xx) 2001-05-21
GB9524137D0 (en) 1996-01-24
CZ158198A3 (cs) 1998-10-14
EP0876348A1 (fr) 1998-11-11
IL124352A0 (en) 1998-12-06
ES2192621T3 (es) 2003-10-16
AR004970A1 (es) 1999-04-07
US6432977B1 (en) 2002-08-13
NZ323389A (en) 2000-02-28
JP2000500770A (ja) 2000-01-25
AU1031997A (en) 1997-06-19
DE69626416D1 (de) 2003-04-03
MX9804106A (es) 1998-09-30
JP4377454B2 (ja) 2009-12-02
EP0876348B1 (fr) 2003-02-26
NO982332D0 (no) 1998-05-22
HUP9903584A2 (hu) 2000-02-28

Similar Documents

Publication Publication Date Title
PL326967A1 (en) Quinoline derivatives
ZA961444B (en) Pyrazolylbenzoyl derivatives.
AP9500745A0 (en) Quinoline derivatives
MX213417B (es) Fenilpiridazinonas.
ZA97521B (en) 19-Nor-pregnene derivatives.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961449B (en) Isoxazolylbenzoyl derivatives.
ZA961955B (en) Indazolecarboxamides.
ZA961697B (en) Indole derivatives.
ZA969221B (en) Indolealkyl derivatives of benzodioxanmethylamine.
HK1018457A1 (en) Alkylaminobenzothiazole and-benzoxazole derivatives.
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA969812B (en) Novel quinoline derivatives.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
GB9404378D0 (en) Quinoline derivatives
ZA966399B (en) Endothelin-receptor-antagonists.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA954269B (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
GB9413150D0 (en) Quinoline derivatives
ZA971167B (en) Heterocyclyl-ergoline derivatives.
CY2322B1 (en) Benzoaeguequinoline derivatives.